Nat Rev Clin Oncol. 2009 Jun;6(6):311-2.

Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression.

Source

Abramson Cancer Center of the University of Pennsylvania, Department of Medicine, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA. bruce.giantonio@uphs.upenn.edu

Abstract

Targeted therapies offer new hope in overcoming the challenges encountered with conventional chemotherapy. However, little is known about the precise mechanisms that cause resistance. These issues are discussed in light of data from the BRiTE study, which indicate that the antiangiogenic effects of bevacizumab might persist despite the development of resistance to first-line chemotherapy.

Comment on

J Clin Oncol. 2008 Nov 20;26(33):5326-34.

PMID:: 19483736; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Comment

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Colorectal Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). [J Clin Oncol. 2008]
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. J Clin Oncol. 2008 Nov 20; 26(33):5326-34. Epub 2008 Oct 14.
Bevacizumab beyond progression: does this make sense? [J Clin Oncol. 2008]
Bevacizumab beyond progression: does this make sense?
Ellis LM, Haller DG. J Clin Oncol. 2008 Nov 20; 26(33):5313-5. Epub 2008 Oct 14.
Review The horizon of antiangiogenic therapy for colorectal cancer. [Oncology (Williston Park). 2005]
Review The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ, Grossbard ML, Kozuch PS. Oncology (Williston Park). 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33.
Review Anti-angiogenic therapies for metastatic colorectal cancer. [Cochrane Database Syst Rev. 2009]
Review Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S. Cochrane Database Syst Rev. 2009 Jul 8; (3):CD005392. Epub 2009 Jul 8.
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. [Oncologist. 2009]
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, et al. Oncologist. 2009 Sep; 14(9):862-70. Epub 2009 Sep 2.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression.
Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression.
Nat Rev Clin Oncol. 2009 Jun ;6(6):311-2.

PubMed
p53 and little brother p53/47: linking IRES activities with protein functions.
p53 and little brother p53/47: linking IRES activities with protein functions.
Oncogene. 2009 Jul 30 ;28(30):2766-72. Epub 2009 Jun 1 .

PubMed
Interleukin 17 acts in synergy with B cell-activating factor to influence B cell...
Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.
Nat Immunol. 2009 Jul ;10(7):778-85. Epub 2009 May 31 .

PubMed
Development of pharmacotherapies for drug addiction: a Rosetta stone approach.
Development of pharmacotherapies for drug addiction: a Rosetta stone approach.
Nat Rev Drug Discov. 2009 Jun ;8(6):500-15.

PubMed
Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from ...
Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion.
Nat Med. 2009 Jun ;15(6):696-700.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: